替格瑞洛抗血小板治疗氯吡格雷抵抗急性心肌梗死经皮冠状动脉介入治疗术后患者的疗效和安全性分析  

Efficacy and safety of tegrilol in the treatment of patients with clopidogrel resistant acute myocardial infarction after percutaneous coronary intervention

作　　者：隋欣桐 马晶茹[1] 金霞[1] SUI Xintong;MA Jingru;JIN Xia(Department of Cardiovascular Medicine,the Second Affiliated Hospital of Shenyang Medical College,Shenyang,Liaoning,110031,China)

机构地区：[1]沈阳医学院附属第二医院心血管内科,辽宁沈阳110031

出　　处：《当代医学》2022年第3期20-22,共3页Contemporary Medicine

摘　　要：目的探究替格瑞洛抗血小板治疗氯吡格雷抵抗急性心肌梗死(AMI)经皮冠状动脉介入治疗(PCI)术后患者的疗效和安全性。方法选取本院2018年8月至2019年12月收治的54例氯吡格雷抵抗AMI患者,按照入院顺序尾数的奇偶数分为研究组和对照组,各27例。所有患者均给予氯吡格雷治疗,其中对照组给予阿司匹林+肝素治疗,研究组给予替格瑞洛治疗。比较两组术后不同时间段血小板聚集率、谷草转氨酶(AST)、血肌酐(SCr)水平及心血管不良事件发生率。结果术后2 h、24 h、7 d,研究组血小板聚集率均低于对照组(P<0.05);术后,研究组AST、SCr水平均高于对照组(P<0.05);术后,研究组心血管不良事件发生率低于对照组(P<0.05)。结论替格瑞洛抗血小板治疗氯吡格雷抵抗急性心肌梗死PCI术后患者效果确切,可有效抑制血小板聚集,改善肝肾功能,且用药安全性高,值得临床推广应用。Objective To explore efficacy and safety of tegrilol in the treatment of patients with clopidogrel resistant acute myocardial infarction after percutaneous coronary intervention(PCI). Methods 54 patients with clopidogrel resistant AMI admitted to our hospital from August 2018 to December 2019 were selected and they were divided into study group and control group according to the odd and even number of the end of the admission order, with 27 cases in each group. All patients were given clopidogrel treatment, the control group was given aspirin + heparin treatment, the study group was given tigril treatment. The platelet aggregation rate, AST, SCr and the incidence of cardiovascular adverse events were compared between the two groups at different time after operation. Results After operation 2 h, 24 h, 7 d, the platelet aggregation rate in the study group were lower than the control group(P<0.05);after operation, the levels of AST, SCr in the study group were higher than those in the control group(P<0.05);after operation, the incidence of cardiovascular adverse events in the study group was lower than that in the control group(P<0.05). Conclusion Tigrilol has effective effect in after PCI in AMI patients with clopidogrel resistance, it can effectively inhibit platelet aggregation, improve liver and kidney function, and has high safety of medication, it’s worthy of promotion.

关 键 词：替格瑞洛 氯吡格雷抵抗 急性心肌梗死 

分 类 号：R542.22[医药卫生—心血管疾病]